Levocarrimycin, in which said levocarrimycin is a mixture of isovalerilespiramicin III, II and I as the main components and contains certain isobutyrylpyrazyrazine III and II, butyrylpyrazpyramine III and II, propionylpyrazine III and II, as well as acetylpyramycin III and II, being among them , the content of isovalerilespiramicin III not less than 30% by weight, the total content of isovalerilespiramicin III, II and I not less than 60% by weight and the content of acylpyrazine 80 to 98% by weight； the specific optical rotation of said levocarrimycin [α] D>； = -52 ° to -57 ° in the solution of 0.02 g / ml of chloroform at a temperature of 25 ° C, in which isovalerilespiramycin III is a crystalline compound of levoisovalerilespiramycin III, isovalerilespiramicin II is a crystalline compound of levoisovalerilespiramycin II, isovalerilespiramycin I is a crystalline compound of levoisovalerilespiramicin I； in which the crystalline compound of isovalerilespiramycin III measured by diffraction of X-ray powder with Cu-K-alpha radiation has characteristic peaks of 2Θ to 8.0º, 10.0º, 11.2º, 11.7º, 16, 4th, 19.1º, 19.6º, 20.0º, 21.4º, 22.9º, 23.6º and 29.4º； The crystalline compound of isovalerilespiramycin II measured by diffraction of X-ray powder with Cu-K-alpha radiation has characteristic peaks of 2Θ to 10.0º, 11.6º, 16.4º, 17.3º, 19.1º, 21 , 2nd, 22.1º, 22.7º, 26.4º, 26.9º, 27.5º and 31.5º； The crystalline compound of isovalerilespiramycin I measured by X-ray powder diffraction with Cu-K-alpha radiation has characteristic peaks of 2Θ at 7.6º, 8.0º, 10.0º, 11.4º, 16.4º, 17 , 0º, 17.5º, 17.9º, 19.5º, 22.7º, 23.7º and 24.4º.Levocarrimicina, en la que dicha levocarrimicina es una mezcla de isovalerilespiramicina III, II y I como componentes principales y contiene determinadas isobutirilespiramicina III y II, butirilespiramicina III y II, propionilespiramicina III y II, así como acetilespiramicina III y II, siendo, entre las mismas, el contenido de la isovalerilespiramici
